With autoimmune pancreatitis linked to a higher cancer risk, doctors must use comprehensive imaging to avoid unnecessary ...

The Emirates Drug Establishment (EDE) has approved new indications for Guselkumab, making the UAE the second country globally to authorise the ...

DelveInsight's "ENTYVIO Market Size, Forecast, and Market Insight Report" highlights the details around ENTYVIO, a gut-selective ...

When symptoms flare up, it can be challenging for people with Crohn’s disease—a chronic inflammatory bowel disease–to ...

Crohn's disease is a chronic, inflammatory condition that causes abdominal cramps, diarrhea, fever, fatigue, weight loss, and ...

The overlap of biologics during medication switches is common in routine care of patients with IBD and isn’t linked to a ...

How might it impact on clinical practice in the foreseeable future? This study provides a basal understanding for the causality of microbe-host interaction in Crohn's disease, based on dynamic ...

Learn about enteropathic arthritis, a common extra-intestinal symptom of Crohn’s disease that affects the joints.

or the worsening of symptoms and inflammation, in inflammatory bowel disease (IBD), Mount Sinai researchers have shown in a first-of-its-kind study. Early treatment of pediatric Crohn's disease ...

Most biologics for Crohn's disease are monoclonal antibody treatments that help tune down the immune system’s overreaction to treat symptoms and help prevent flare-ups. These treatments have led to ...

Notably, among Crohn's disease (CD) patients ... up to age 5 years before clinical presentation. Interestingly, while healthy infants also exhibited elevated IgG reactivity to these epitopes ...

Results showed in GALAXI 2, 47% of patients treated with guselkumab had clinical remission (defined as a Crohn Disease Activity Index [CDAI] score <150) at week 12 compared with 20% of patients who ...